Overview
I am an Assistant Professor of Medical Oncology who primarily treats patients with colon cancer and gastroesophageal cancers, where I also conduct early phase immunotherapeutic trials. My laboratory and translational research are focused on tumor immune evasion and immunotherapy, particularly in the setting of metastasis. This work has led to a specific interest in tumor-mediated development of dendritic cell tolerance and suppressive myeloid populations. The ultimate goal of these studies is to create biomarker-directed immunotherapies for advanced gastrointestinal cancers.
Current Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors.
Journal Article J Clin Oncol · March 2026 Full text Link to item CiteTumor NLRP3 Amplification Promotes Immunotherapy Resistance by Suppressing MHC Class I Expression.
Journal Article medRxiv · October 7, 2025 Immunotherapy resistance remains a major challenge in immuno-oncology. We have previously demonstrated that a tumor-intrinsic NLRP3 inflammasome signaling pathway promotes adaptive immunotherapy resistance by inducing the recruitment of granulocytic myeloi ... Full text Link to item Cite2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, advanced solid tumors: Phase I/Ib trial
Conference Annals of Oncology · September 2025 Full text CiteRecent Grants
A Phase1b/2, multicenter, randomized, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable or metastatic gastrointestinal solid tumors
Clinical TrialPrincipal Investigator · Awarded by GlaxoSmithKline · 2025 - 2030A Phase 1b Study of Neoadjuvant ASP2138 Monotherapy and Investigator?s Choice of Adjuvant Chemotherapy in Participants with Resectable Pancreatic Ductal Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression (2138-CL-0102)
Clinical TrialPrincipal Investigator · Awarded by Astellas Pharma Global Development, Inc · 2025 - 2030A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal
Clinical TrialPrincipal Investigator · Awarded by Legend Biotech USA, Inc. · 2025 - 2030View All Grants
Education
University of South Florida, College of Medicine ·
2012
M.D.